drugset / Trial / NCT00774475

Dual Antiplatelet Therapy Tailored on the Extent of Platelet Inhibition

NCT00774475

Phase 3 Unknown 442 enrolled University of Florence Tuscany Region · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy (reduction of major ischemic events at 6 and 12 months of follow-up) of a tailored clopidogrel therapy in patients with UA/NSTEMI undergoing PCI with stent implantation and wiht a documented residual platelet reactivity assessed by a point of care system (VerifyNow P2Y12).

Timeline

Start
2008-11
Primary completion
2010-11
Completion
2011-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Clopidogrel Small molecule 75 mg
Comparator Clopidogrel Small molecule 150 mg